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Abstract
Protein zero (P0) is the major structural protein in peripheral myelin, and mutations in the Myelin Protein Zero (Mpz) gene
produce wide-ranging hereditary neuropathy phenotypes. To gain insight in the mechanisms underlying a particularly
severe form, congenital hypomyelination (CH), we targeted mouse Mpz to encode P0Q215X, a nonsense mutation associated
with the disease, that we show escapes nonsense mediated decay and is expressed in CH patient nerves. The knock-in mice
express low levels of the resulting truncated protein, producing a milder phenotype when compared to patients, allowing to
dissect the subtle pathogenic mechanisms occurring in otherwise very compromised peripheral myelin. We find that
P0Q215X does not elicit an unfolded protein response, which is a key mechanism for other pathogenic MPZ mutations, but is
instead in part aberrantly trafficked to non-myelin plasma membranes and induces defects in radial sorting of axons by
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addition is able to restore correct P0Q215X trafficking in vitro. Lastly, we show that P0Q215X acts through dose-dependent
gain of abnormal function, as wild-type P0 is unable to rescue the hypomyelination phenotype. Collectively, these data
indicate that alterations at the premyelinating stage, linked to altered targeting of P0, may be responsible for CH, and that
different types of gain of abnormal function produce the diverse neuropathy phenotypes associated with MPZ, supporting
future allele-specific therapeutic silencing strategies.
Introduction
Mutations in themyelin protein zero (MPZ) gene are a major cause
of inherited neuropathy and can manifest in a wide range of
clinical phenotypes, ranging from early-onset forms, as Dejer-
ine–Sottas syndrome (DSS) and congenital hypomyelination
(CH), to less severe, adult onset, Charcot–Marie–Tooth diseases
(CMT) [18,23].
Protein zero (P0), encoded by the MPZ gene, is primarily
expressed in Schwann cells (SCs) and is the major structural
transmembrane protein in peripheral myelin. P0 plays a crucial
role in myelin formation by compacting adjacent wraps of SC
plasma membrane, through in trans homophilic adhesion of
its extracellular domain [3,5,8,20]. To date there are over 100
mutations in MPZ, known to cause peripheral neuropathies in
patients and, although most of them are located in the extra-
cellular domain of P0, few mutations in the short cytoplasmic
domain were also reported [2,23]. The intracellular tail of P0 has
several putative functions including compacting the cytoplasmic
apposition in myelin [14], modulating adhesion by the P0
ectodomain [24,25,28] and directing trafficking of P0 through
the YAML motif [12].
We have previously shown that different MPZ mutations
act through distinct pathogenic mechanisms [15,27]. To further
our understanding of how MPZ mutations cause disease, we
generated a mouse model carrying the MPZQ215X mutation,
which should eliminate part of the cytoplasmic domain and
causes the severe CH neuropathy [13,21,23]. Here we show that
lack of the last 33 amino acids induces an altered trafficking of
the protein to non-myelin plasma membranes and is associated
with altered radial axonal sorting by SCs in the early phases
of myelination. We demonstrate that Mpz Q215X acts through
a dose-dependent, gain of abnormal function that cannot
be rescued by supplementing normal P0, carrying important
implications for therapeutic strategies.
Results
Q215X escapes NMD and MpzQ215X/+ mice express low
levels of mutant P0
The CH-causative MPZ Q215X mutation induces a premature
stop codon and, due to its location in the penultimate exon,
has been predicted to escape nonsense mediated decay (NMD)
[10,11]. We therefore first tested the expression of the mutant
and wild-type (WT) MPZ alleles from a skin biopsy of a patient
carrying this mutation and found equal expression levels of
the two alleles, supporting the prediction that the mutation
is not subject to NMD (Fig. 1A). To allow disease mecha-
nism investigations, we generated knock-in mouse lines by
homologous recombination in embryonic stem (ES) cells
(Supplementary Material, Fig. S1).We generated ES cells carrying
the Q215X mutation and two control lines (LoxPA3 and LoxPD1),
where we inserted the WT sequence. Q215X heterozygous
(MpzQ215X/+) and homozygous (MpzQ215X/Q215X) mice along with
LoxP controls (MpzLoxP/+ and MpzLoxP/LoxP) were all viable. The
Q215X mutation is predicted to encode for a truncated P0,
lacking 33 amino acids of its C-terminal intracellular domain.
Western blot analysis on sciatic nerve (SN) protein extracts
of P28 WT, MpzQ215X/+and MpzQ215X/Q215X mice confirmed the
mutation produces a smaller P0 with a molecular weight of
∼24 kDa (Fig. 1B and F). Surprisingly, the amount of the mutated
protein was strongly reduced relative to endogenous P0. We
therefore tested the levels ofMpz RNA and observed a reduction
to 25% of WT levels (Fig. 1D and E). The mouse Q215X transcript
was not targeted by NMD (Supplementary Material, Fig. S2), as
predicted from patient data that was previously mentioned,
and the reduction in expression was present also in control
lines carrying only the LoxP site (Fig. 1D and E). Importantly,
although the presence of LoxP accounts for a reduction at
the RNA level, the amount of truncated protein was reduced
in Q215X homozygous nerves compared to equally expressing
LoxP homozygous nerves, suggesting that the mutation affects
the protein stability (Fig. 1F and G). Thus, the Q215X knock-in
mouse generated a truncated protein that was expressed at low
levels, probably due to the combined effect of the LoxP site at the
transcriptional level and of the truncation at the protein level.
MpzQ215X/+ mice develop a neuropathy with radial
sorting defects
Whilst the Q215X mutation in patients induces an early disease
onset and severe clinical features, the MpzQ215X/+mice showed
no gross phenotype compared to controls and did not reveal any
external sign of peripheral neuropathy (gait difficulty, tremor,
atrophy of the hind limb musculature). In order to assess
whether the mutant P0Q215X induces nerve abnormalities, we
analysed semi-thin sections (STSs) of P28 SNs from MpzQ215X/+
mice, which revealed a mild hypomyelination when compared
to controls (Fig. 2A). G-ratio analysis to assess myelin thickness
confirmed the hypomyelination in MpzQ215X/+ and showed that
was similar to the hypomyelination seen in P0 heterozygous
knockout (Mpz+/−) mice, which served as control for reduced
Mpz expression (G-ratio Q215X/+0.69, P0+/−0.7,WT 0.65; Fig. 2B).
In patients, the Q215X mutation causes a deficit during
development; we thus focused our analysis in the first 2
weeks of postnatal life. At P11, we observed bundles of
unsorted mixed caliber axons in MpzQ215X/+ nerves (Fig. 2C,
arrowheads) and not in WT littermates or in Mpz+/− mice
(Fig. 2C). Unsorted axons were significantly augmented in
MpzQ215X/+ compared to both WT and Mpz+/- mice (Fig. 2D, E),
and at P14, the radial sorting defect was not visible anymore
(data not shown) indicating that the deficit in P11 MpzQ215X/+
mice is that of a delay in myelination. We tested whether this
defect resulted in a neuromuscular deficit using the rotarod
and grid-walking tests. MpzQ215X/+ P10 to P12 mice showed
a significant reduction in motor coordination compared to
controls, revealing that the transient defect in the process of
myelination identified in P11 mice results in a developmental
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Figure 1. Q215X escapes NMD and MpzQ215X/+ mice express low levels of truncated protein. (A) Retrotranscribed and amplified MPZ RNA from a skin biopsy of a
patient carrying the Q215X mutation shows similar expression of the mutated (uncut with Fnu4HI) and WT (cut) alleles. As expected, all transcripts are WT (cut) in a
control sample. (B) Western blot using anti-P0 and anti-βTubulin on protein extracts from SNs of Mpz+/+ ,MpzQ215X/+ and MpzQ215X/Q215X sacrificed at postnatal day
28 show the presence of a truncated form of the protein at 23kD. (C) Schematic representation of the DpnII restriction enzyme sites in the different Mpz alleles. (D)
DpnII restriction enzyme digestion of the retrotranscription (RT)-polymerase chain reaction (PCR)-amplified cDNA, obtained from RNA extracted from Mpz+/+ (mice
Friend Virus B mice (FVB)/C57Bl6),MpzQ215X/+ (129SVPas/C57Bl6) and two independent lines of MpzLoxP/+ (129SVPas/C57Bl6) P28 SNs. Given all targeted vectors were
generated on 129SVPas background, and therefore did not carry the DpnII restriction site, we crossed all to C57Bl6 background, where the wt Mpz allele does have a
DpnII restriction site. This allowed differentiation of WT Mpz (cut) and targeted alleles (uncut) by digestion. A WT mouse carrying one FVB allele (uncut) and C57Bl6
allele (cut) was used as technical control and showed equal amounts of expression from the two alleles. (E) Quantification of uncut band versus digested product
(FVB WT transcript) are plotted showing a similar reduction in all samples carrying the LoxP site (n = 3 mice/genotype; one-way ANOVA, Tukey’s post-test, P-value ns
between samples carrying the LoxP site. Error bars represent SEM). (F) Anti-P0 western blot of protein extracts fromMpz+/+ ,MpzLoxP/LoxP and MpzQ215X/Q215X p28 SNs.
(G) Quantification of P0 normalized to calnexin is shown (n = 3 mice/genotype; two-way ANOVA, Bonferroni post-test, P < 0.001 versus WT. Error bars represent SEM).
using the grid walking test where P15 MpzQ215X/+ mice had a
significantly higher number of errors compared to controls
(analysis of variance [ANOVA] genotype effect F[1,65] = 8.33;
P = 0.005, normalized on the same number of steps: ANOVA
genotype effect F[1,65] = 0.4; P = 0.52) (Fig. 2G). These
neuromuscular deficits are not present anymore in adult (P28)
mice (data not shown). Taken together, these data show that
the Q215X mutation, even expressed at low levels, induces
an axonal radial sorting defect with delay in myelination
leading to a dysmyelinating neuropathy. This early defect in
postnatal life parallels the dysmyelinating disease reported
for the two patients presenting Q215X de novo mutations
and is specifically due to the presence of the Q215X-mutated
glycoprotein and not to the lower expression of Mpz, as
demonstrated by the absence of unsorted bundles of large
caliber axons in P0+/− mice. These observations collec-
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Figure 2. P0Q215X induces radial axonal sorting defects and neuropathy. (A) STSs of p28 SNs taken from Mpz+/+ ,Mpz+/− and MpzQ215X/+ mice. Magnification, 100X;
scale bar, 10 μm. (B) G-ratio quantifications of (A) (g-ratio Mpz+/+ 0.65+/−0.002; g-ratio Mpz+/− 0.7+/−0.002; g-ratio MpzQ215X/+ 0.69+/−0.002); n = 5 mice/genotype,
paired t-test, P < 0.001 versus WT. Error bars represent SEM). (C) STS of p11 SNs fromMpz+/+ ,Mpz+/− andMpzQ215X/+ mice. Arrowheads indicate bundles of unsorted
axons. (D) Electromicrographs of p11 SNs taken from Mpz+/+ , Mpz+/− and MpzQ215X/+ mice, showing details of bundles of unsorted axons (magnification, 20,000x;
scale bar, 1 μm). (E) Number of unsorted axons (in direct contact with other axons, indicated by asterisks in the right panel) within the bundles, with a diameter >
1 μm (n = 3 mice/genotype, one-way ANOVA, Tukey test, P < 0.001 versus WT. Error bars represent SEM). (F) Rotarod analysis shows thatMpzQ215X/+ mice at P11 (n = 72)
remain on the accelerating cylinder for significantly less time than WT littermates (n = 57). Paired t-test, ∗P < 0.05 and ∗∗P < 0.01 versus WT. Error bars represent SEM.
(G) Grid-walking test shows thatMpzQ215X/+ mice at P15 (n = 32) had a number of errors as compared toWT littermate controls (Mpz+/+ ; n = 35) with the same number
of total steps. ANOVA genotype effect for errors F[1,65] = 8.33; P = 0.005. Error bars represent SEM.
P0Q215X does not induce ER stress and reaches the
plasma membrane
Altered intracellular retention inducing ER stress has been
previously associated and shown to play a crucial role in the
pathogenesis of GOF MPZ mutations [15,17,27], prompting us to
investigate whether P0Q215X induces ER stress and an unfolded
protein response.
First, we generated MpzQ215X/Q215X, which only expresses the
mutant protein, and determined whether P0Q215X was retained
in the ER by performing co-staining with the ER marker KDEL
on teased nerve fibers. We compared MpzQ215X/Q215X to WT mice
(Fig. 3A) and also to LoxP homozygous (MpzLoxP/LoxP) mice (Fig. 3B),
which have a similar amount of Mpz expression. We could not
detect P0Q215X in the ER (Fig. 3C), differently from P0S63del
that we used as a positive control (Fig. 3D). Furthermore, mRNA
levels of ER stress transcripts BiP and spliced Xbp-1 were not
significantly increased in MpzQ215X/Q215X nerves, in contrast to
nerves from mice carrying the P0S63del mutation, showing that
the Q215X mutation does not induce ER stress (Fig. 3E). P0Q215X
was detected in the myelin of teased nerve fibers (Fig 3C),
suggesting it can be normally trafficked. P0 forms tetramers
before being targeted tomyelin, and we tested whether P0Q215X
is able to interact with its WT counterpart. We generated
MpzQ215X/Q215X mice expressing a myc-tagged P0WT (P0myc),
allowing to perform an immunoprecipitation assay using an
anti-myc antibody, in this setting specific to P0WT [6]. Western
blot analysis of immunoprecipitates demonstrated pulldown
of P0Q215X, supporting the interaction between P0Q215X and
WTP0 (Supplementary Material, Fig. S2). Overall, this data shows
that P0Q215X reach the plasma membrane, does not induce ER
stress and can interact with P0WT.
P0Q215X is incorrectly trafficked to non-myelin plasma
membranes
As the C-terminal domain has been shown to be important
in targeting P0 to the membrane, we performed immunoelec-
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Figure 3. Lack of the YAML motif induces P0Q215X mistrafficking to non-myelin membrane. Immunohistochemistry on teased SN fibers from MpzQ215X/Q215X (C) and
MpzLoxP/LoxP (B) mice show P0 ER retention inMpz+/+//P063del mice (D) but not inMpzQ215X/Q215X andWT controls (A). DAPI (blue), P0 (red), KDEL (green). Scale bar, 35 μm.
(E) qPCR quantifications of XBP-1 and BiP levels show no significant changes inMpzQ215X/Q215X (n = 3 mice/genotype; one-way ANOVA, Tukey’s post-test. P-value versus
WT ns and <0.001 (∗∗∗∗). Error bars represent SEM). (F, G) IEM using anti-P0 Ab onMpzQ215X/Q215X andMpz+/− p10 SNs (scale bar, 500 nm). Asterisks show gold granules
detected mainly in the compact myelin in bothMpzQ215X/Q215X andMpz+/− p10 SNs, whereas arrows indicate P0 in non-myelin plasma membranes inMpzQ215X/Q215X
SNs. (H) Quantification of gold granules counted in non-myelin plasma membranes shows a statistically significant difference between MpzQ215X/Q215X and Mpz+/−
(n = 3 mice/genotype paired; t-test, P < 0.0001; error bars represent SEM). Transiently transfected MDCK cells expressing P0Q215X-YAML-HA, or P0Q215X-HA and P0WT-
HA as controls, were stained for HA (red), ZO1 (blue, marker of basolateral surface) and Beta-catenin (green, marker of apical surface). Three independent replicates. (I)
P0WT-HA is targeted to the basolateral surface of MDCK cells: in XZ confocal images, P0 immunostaining did not colocalize with apical marker Beta-catenin but was
concentrated in basolateral membranes, which are immunostained for ZO1. (J) P0Q215X-HA was targeted to the apical surface and/or accumulated throughout the cell.
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Figure 4. P0Q215X acts through gain of abnormal function. (A) STS of SNs from P10 MpzLoxP/LoxP and MpzQ215X/Q215X mice.MpzQ215X/Q215X nerves are hypomyelinated
when compared toMpzLoxP/LoxP nerves (scale bar 10 μm). (B) STS of P10 nerves fromMpzQ215X/Q215X (upper panel, at left) and fromMpzQ215X/Q215X mice overexpressing
P0WT (MpzQ215X/Q215X;tgP0oe, upper panel, at right); STS of P10 nerves fromMpz−/− (lower panel, at left) andMpz−/− overexpressing P0WT (Mpz−/−;tgP0oe , lower panel,
at right); scale bar, 10 μm. Restoration of normal levels of P0wt is unable to rescue the hypomyelination inMpzQ215X/Q215X;tgP0oe (upper panel, at right), whereas it does
rescue the very severe hypomyelination in Mpz−/−;tgP0oe (lower panel, at right). In A and B, the red and the green bars indicate the expression of the WT (green) or
mutated (red) alleles. (C) G ratio measured at P10 shows hypomyelination in MpzQ215X/Q215X;tgP0oe, whereas hypomyelination is rescued in Mpz−/−;tgP0oe , where the G
ratio is comparable to WT mice. G-ratio values: WT 0.63; Mpz−/− 0.76; Mpz−/−;tgP0oe 0.63; MpzQ215X/Q215X 0.75; MpzQ215X/Q215X;tgP0oe 0.74. n = 5 mice/genotype; paired
t-test: P < 0.0001Mpz−/− versusMpz−/−;tgP0oe and P-value ns MpzQ215X/Q215X versusMpzQ215X/Q215X;tgP0oe. Error bars represent SEM. (D) Electron micrographs confirms
the rescue of myelin thickness inMpz−/−;tgP0oe at P10 (right image), whereas hypomyelination and the sorting defects still remain inMpzQ215X/Q215X;tgP0oe (left image).
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assess this process. Gold granules indicate that P0 molecules are
located primarily in the myelin sheath in Mpz+/− nerves (Fig. 3F
and G, asterisks) and show that P0Q215X can still reach and can
still be retained in compact myelin in MpzQ215X/Q215X nerves, but
interestingly, gold granules were also frequently detected out-
side ofmyelin inMpzQ215X/Q215X nerves (Fig. 3G,arrows) suggesting
that P0Q215X could be partially mistrafficked to non-myelin
plasma membranes surrounding the SC body. Quantification of
P0 showed an increase of the number of gold granules in non-
myelin plasma membranes from MpzQ215X/Q215X nerves, which is
significantly higher than in the Mpz+/− controls (Fig. 3H). These
data demonstrate that P0Q215X trafficking is altered in vivowith
P0 being targeted to non-compact myelin membranes.
The YAML sequence in the cytoplasmic tail regulates
P0 trafficking
P0Q215X lacks a YAML sequence in its C-terminal region, which
has previously been implicated in myelin membrane targeting
[12]. In order to address whether this determines the altered
trafficking of P0Q215X, we used an in vitro assay where the
YAML motif directs P0 trafficking to the basolateral surface of
transfected and polarizedMDCK cells [12].We transfectedMDCK
cells with P0Q215X-HA or P0Q215X-YAML-HA and P0wt-HA as
control, and stained the cells for hemagglutinin (HA), for Beta-
catenin, a marker of the apical junction, and for ZO1, amarker of
the basolateral surface. P0WT-HA was present at the basolateral
surface of the cells (Fig. 3I), whereas themutant P0Q215X-HA did
not respect the basolateral distribution and was detected also
at the apical surface (Fig. 3J). In contrast, the P0Q215X-YAML-HA
construct was detected only at the basolateral surface of MDCK
cells (Fig. 3K). These data show that YAML is sufficient to restore
proper surface membrane targeting of P0Q215X, suggesting its
deficiency determines the observed altered targeting of P0Q215X.
P0Q215X acts through a gain of abnormal function
Whether mutations act tough, gain- or loss-of-function is
a crucial information as it has implications for therapeutic
approaches. We reasoned that if the phenotype observed in
MpzQ215X/Q215X mice was due to hypomorphic P0 expression,
i.e. a loss of function, then MpzLoxP/LoxP should have a similar
phenotype, whilst if GOF were involved, the phenotype should
be aggravated in a dose-dependent manner. To therefore test
whether Q215X induces disease by a dosage-dependent GOF, we
first generatedMpzQ215X/Q215X mice andwe comparedmyelination
to that of MpzLoxP/LoxP mice, that express equivalent levels of
wt Mpz. Whilst the reduced amount of WT Mpz expressed in
MpzLoxP/LoxP mice (∼20% of normal) was sufficient for myelination
in SNs at P10, MpzQ215X/Q215X animals (also expressing ∼20%
of normal) manifested a very severe hypomyelination at this
age (Fig. 4A). To further eliminate the confounding element of
LOF in MpzQ215X/Q215X mice, we crossed MpzQ215X/Q215X mice with
a P0 overexpressor transgenic mouse line (Mpz+/+;tgP0oe) [26].
The Mpz+/+;tgP0oe mice express Mpz wt at 80% on top of normal
(where normal refers to twoMpz wt alleles) and were previously
demonstrated to fully rescue the P0 null phenotype at P28 [26].
We compared MpzQ215X/Q215X;tgP0oe mice to Mpz−/−;tgP0oe mice at
P10. Consistent with previous results STS from Mpz−/−;tgP0oe SNs
show normal myelination (Fig. 4B) with a G-ratio similar to WT
(Fig. 4C; G-ratio values: WT 0.63; P0ko 0.76; P0ko//P0oe 0.63).
Electron microscopic (EM) analysis confirmed the presence of
normally compacted, thick myelin sheaths in these specimens
(Fig. 4D)—demonstrating that the P0oe transgene is able to
rescue the Mpz−/− phenotype also at P10. In contrast, STS from
MpzQ215X/Q215X;tgP0oe SNs showed abnormally thin myelin (Fig. 4B).
EM analysis showed bundles of unsorted axons as previously
described and, most remarkably, very severe hypomyelination
in SN (Fig. 4D). P0WT was unable to induce an amelioration
when compared to MpzQ215X/Q215X, and the G-ratio was not
significantly different (Fig. 4C; G-ratio values: Q215X/Q215X 0.75;
Q215X/Q215X//P0oe 0.74). These data conclusively demonstrate
that Q215X causes the myelin phenotype by a dose-dependent
GOF mechanism.
Discussion
We have generated a novel mouse model for CH induced by a
nonsenseMPZmutation.We first show, using patient tissue, that
the mutation escapes NMD and is expressed similarly to its WT
counterpart. In both ourmutantmice and in control lines,where
aWT-Mpz allelewas inserted and therefore carry a LoxP site,Mpz
expression is reduced due to the presence of the LoxP sites in
intron 5, and, as expected, the premature stop codon gives rise
to a truncated protein in mice. This provides a model system
where a very aggressive mutation is expressed at more limited
levels, potentially allowing us to discern more subtle pheno-
types. Recently developed and nowwidely used approacheswith
CRISPR-Cas9 would be predicted to not influence the expression
levels and we would therefore expect a more severe phenotype
to develop. Interestingly, protein levels appear lower compared
to WT LoxP alleles, suggesting reduced protein stability. The
mutant heterozygous mice, in keeping with the reduced expres-
sion of mutant Mpz, develop a phenotype that is less severe
than that of patients, but nonetheless show hypomyelination.
We were also able to identify a novel defect in axonal radial
sorting during myelination at P10, which is intriguing, as defects
at the axonal sorting stage are compatible with the early-onset
developmental phenotype observed in patients.
Normally P0 is synthesized in the ER, glycosylated, assembled
as tetramers and then targeted to the myelin membrane, and
early stages of this process have been shown to be altered in
other disease-causing mutations [15,17,27]. We therefore used
a combination of molecular mouse tools, biochemical, confocal
microscopy and IEM approaches to investigate P0Q215Xmatura-
tion, and show that P0Q215X is able to correctly mature, interact
with its WT counterpart and be trafficked to the membrane. No
ER stress is induced, clearly differentiating the mechanism of
action from other MPZ mutations causative of CMT or CH that
we previously characterized in mice [15,17,27].
As one of the known functions for P0 cytoplasmic domain,
which is truncated in P0Q215X, is to target the protein to myelin
[12],we analyzed in detail themembrane targeting of the protein,
and found that Q215X was increasingly misdirected to non-
myelin plasma membranes. We then used an in vitro assay to
show that reinsertion of the YAML in the cytoplasmic domain
is able to rescue the trafficking of P0Q215X. Interestingly, even
WT P0, if overexpressed at very high levels, is mislocalized at
the abaxonal membrane and mesaxon, causing CH due to radial
sorting defects and amyelination. The latter is probably due to a
gain of normal P0 function that causes homophilic P0 adhesion
between apposed mesaxonal membranes [26,29]. These findings
have important implications as, potentially, the targeting of an
adhesive protein such as P0 to incorrect membrane domains
may contribute also to the altered axonal radial sorting process,
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The mistargeting of P0 protein is compatible in principle
with both gain- and loss-of-function mechanisms. Dissecting
the contribution of gain and loss of function is extremely impor-
tant, especially in light of the recent increase in genetic therapy
approaches, where for example PMP22 is targeted for reduction
by means of antisense oligonucleotides in a CMT1A [30]. Our
findings of an axonal sorting phenotype being present only in
MpzQ215X/+ andnot inMpz+/− mice suggested= aGOF and in order
to conclusively address this issue, we increased the dosage of
mutant P0Q215X by breeding mice to homozygosity and then
asked whether supplementation of P0WT protein would rescue
the phenotype. Homozygous mice showed a very severe pheno-
type, but P0WT supplementation, which was able to rescue the
full loss of P0 inMpz−/− mice, was unable to correct the P0Q215X
toxicity, strongly indicating GOF as the main mode of action.
The fact that different MPZ mutations have very distinct
mechanisms of action, but the commonality of a GOF mecha-
nism, has strong therapeutic implications. It makes it unlikely
to develop a therapeutic approach targeting such awide range of
biological processes (e.g. altered membrane targeting, ER stress
etc.), but supports a genetic therapeutic approach based on
allele-specific knock down. Although, currently, gene silencing
is being pursued only in conditions where the same mutation
is present in a wide number of patients (e.g. CMT1A), future
developments may use common polymorphism to develop an
array of silencing tools. This will allow for a silencing approach
to be applied to less frequent mutations such MPZ.
Materials and Methods
All materials and methods can be found in the Supplementary
Materials.
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